🟠 Conclusions: BCL6-targeted therapies could revolutionize weight-loss treatments by minimizing muscle loss. 
Continued exploration of BCL6 pathways may optimize GLP-1 medications and improve outcomes for various muscle-wasting conditions. 
#obesity #glp1 #weightloss #biotech @FDA $NVO $ALUR $SNY $SAN
#obesity #glp1 #weightloss #biotech